Clinical characteristics and analysis of prognostic factors in methicillin-resistant Staphylococcus aureus endocarditis: A retrospective multicenter study in Japan.
Endocarditis
Methicillin-resistant Staphylococcus aureus
Multi-organ failure
prognosis
surgical treatment
Journal
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
received:
14
12
2023
revised:
16
05
2024
accepted:
10
06
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
Infective endocarditis (IE) caused by MRSA (methicillin-resistant Staphylococcus aureus) is associated with a high mortality rate. This study aimed to elucidate the characteristics of patients with MRSA-IE in Japan and identify the factors associated with prognosis. This retrospective study included patients with a confirmed diagnosis of IE caused by MRSA, between January 2015 and April 2019. A total of 65 patients from 19 centers were included, with a mean age of 67 years and 26% were female. Fifty percent of the patients with IE were had nosocomial infections and 25% had prosthetic valve involvement. The most common comorbidities were hemodialysis (20%) and diabetes (20%). Congestive heart failure was present in 86% of patients (NYHA class I, II: 48%; III, IV: 38%). The 30-day and in-hospital mortality rates were 29% and 46%, respectively. Multi-organ failure was the primary cause of death, accounting for 43% of all causes of death. Prognostic factors for in-hospital mortality were age, disseminated intravascular coagulation, daptomycin and/or linezolid as initial antibiotic therapy, and surgery. Surgical treatment was associated with a lower mortality rate (odds ratio [OR], 0.026; 95% confidence interval [CI], 0.002-0.382; p=0.008 for 30-day mortality and OR, 0.130; 95% CI; 0.029-0.584; p=0.008 for in-hospital mortality). Mortality due to MRSA-IE remains high. Surgical treatment is a significant prognostic predictor of MRSA-IE.
Sections du résumé
BACKGROUND
BACKGROUND
Infective endocarditis (IE) caused by MRSA (methicillin-resistant Staphylococcus aureus) is associated with a high mortality rate. This study aimed to elucidate the characteristics of patients with MRSA-IE in Japan and identify the factors associated with prognosis.
METHODS
METHODS
This retrospective study included patients with a confirmed diagnosis of IE caused by MRSA, between January 2015 and April 2019.
RESULTS
RESULTS
A total of 65 patients from 19 centers were included, with a mean age of 67 years and 26% were female. Fifty percent of the patients with IE were had nosocomial infections and 25% had prosthetic valve involvement. The most common comorbidities were hemodialysis (20%) and diabetes (20%). Congestive heart failure was present in 86% of patients (NYHA class I, II: 48%; III, IV: 38%). The 30-day and in-hospital mortality rates were 29% and 46%, respectively. Multi-organ failure was the primary cause of death, accounting for 43% of all causes of death. Prognostic factors for in-hospital mortality were age, disseminated intravascular coagulation, daptomycin and/or linezolid as initial antibiotic therapy, and surgery. Surgical treatment was associated with a lower mortality rate (odds ratio [OR], 0.026; 95% confidence interval [CI], 0.002-0.382; p=0.008 for 30-day mortality and OR, 0.130; 95% CI; 0.029-0.584; p=0.008 for in-hospital mortality).
CONCLUSION
CONCLUSIONS
Mortality due to MRSA-IE remains high. Surgical treatment is a significant prognostic predictor of MRSA-IE.
Identifiants
pubmed: 38876203
pii: S1341-321X(24)00157-0
doi: 10.1016/j.jiac.2024.06.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Tokimatsu I. received scholarship donations from Shionogi Pharmaceuticals, Inc. and Daiichi Sankyo Co., Ltd. Ukimura A. received scholarship donations from Shionogi Pharmaceuticals Inc. Hiroshige Mikamo received speaker honoraria from MSD K.K., FUJIFILM Toyama Chemical Co., Ltd., Miyarisan Pharmaceutical Co., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Sumitomo Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Japan. Ltd., Kowa Co. Ltd., Gilead Sciences K.K., the GSK Group of Companies, Saraya Co. Ltd., and Tsumura and Co. Japan, Nippon Becton Dickinson Company, Ltd., and FUKOKU Co., Ltd., and grant support from Asai Kasei Pharma Co., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and FUKOKU Co., Ltd. Mitsutake K, Shinya N, Seki M, Ohara T, Uemura K, Fukunaga M, Sakai J, Nagao M, Sata M, Hamada Y, Kawasuji H, Yamamoto Y, Nakamatsu M, Koizumi Y, Aoyagi T, Sawai T, Tanaka T, Izumikawa K, Takayama Y, Nakamura K, Kanemitsu K, Nakajima K, and Akine D have no conflict of interest.